一名辉瑞发言人称，警告信主要和一项在36个临床基地用Geodon治疗双重人格症的研究。
A Pfizer spokeswoman said the letter primarily related to one main study of Geodon that was conducted for bipolar disorder at 36 clinical sites.
研究人员认为，这项发现对治疗恐慌症和创伤后应激障碍患者有临床意义。
The researchers suggest the finding has implications for the treatment of patients with panic disorder or PTSD.
研究的另一个优势是，有组织的临床采访曾经用于诊断自闭症，这是以前的许多研究没有的。
Another strength of the study is that structured clinical interviews were used to diagnose autism, which was not the case with many previous studies.
应用推荐